Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 10/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.32 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.32 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282904 | 0.82 | PTGS2 (0.49) | PTGS2PTGS1ESR1LMNAMEN1 | |
| SCHEMBL1513625 | 0.78 | ESR1 (0.43) | ESR1ESR2 | |
| SCHEMBL6282870 | 0.77 | PTGS2 (0.43) | PTGS2PTGS1LMNAMEN1MAPT | |
| SCHEMBL6283123 | 0.75 | MMP3 (0.46) | PTGS2PTGS1ESR1LMNAMEN1 | |
| SCHEMBL6279628 | 0.74 | KMT2A (0.45) | PTGS2PTGS1ESR1LMNAMEN1 | |
| SCHEMBL6286433 | 0.74 | PTGS2 (0.47) | PTGS2PTGS1ESR1LMNAMEN1 | |
| SCHEMBL6287408 | 0.74 | KMT2A (0.45) | PTGS2PTGS1ESR1LMNAMEN1 | |
| SCHEMBL28427770 | 0.69 | HDAC3 (0.43) | ESR1MEN1MAPTKMT2AESR2 | |
| SCHEMBL7211950 | 0.69 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL7216178 | 0.69 | PTGS2 (0.74) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | PTGS2 4202/4885PTGS1 2849/4885ESR1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.